Clinical Trial: Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07836036) titled 'Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations' on Sept. 14.

Brief Summary: This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ASKC189 in in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Solid Tumor RAS Mutation

Intervention: DRUG: ASKC189

ASKC189 for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.

Recruitment Status: NOT_YET_RECRUITING

Spon...